Other ways to search: Events Calendar | UTHSC

We finally have new drugs for sickle cell disease. Why are so few patients taking them?


A string of trials are underway to prove benefits across different organs, including reducing the risk of developing kidney failure or leg ulcers, alongside strokes. But results could be years away.

“It does have the potential to decrease other complications,” said Kenneth Ataga, Director of the Center for Sickle Cell Disease at University of Tennessee Health Science Center. “But until we have those data, we just can’t use [Oxbryta] for those other indications.”

Top Publishers